Medical
-
A report by the American Lung Association in California claims that a “car of the future” scenario in which zero emission vehicles replace a large percentage of the existing fleet of cars in the state… Read more . . .
-
GSK and AstraZeneca have announced that the two companies, along with the University of Manchester, are working together to create the Manchester Collaborative Centre for Inflammation Research (MCCIR) to facilitate translational research in inflammatory diseases,… Read more . . .
-
An article in the May 5 issue of the New England Journal of Medicine finds leukotriene-receptor antagonists (LTRAs) such as montelukast (Singulair) as effective as ICS as a first-line treatment for asthma and as effective… Read more . . .
-
A Phase 2 clinical trial of its bepotastine besilate nasal spray for the treatment of seasonal allergic rhinitis has demonstrated significantly significant improvement in total nasal symptoms compared to placebo, announced ISTA Pharmaceuticals. The study… Read more . . .
-
The University of Michigan will license an antigen to NanoBio Corporation for development of a nasal vaccine using NanoBio’s NanoStat technology for the prevention of urinary tract infections (UTIs). The antigen works by eliminating E.… Read more . . .
-
NVA237, a once daily, long acting muscarinic agent (LAMA) DPI for the treatment of COPD, met its primary endpoint of improved bronchodilation compared to placebo after 12 weeks. The glycopyrronium bromide dry powder formulation was… Read more . . .
-
Dennis Metzger of Albany Medical College (Albany, New York) has presented research at the Society for General Microbiology Spring Conference demonstrating the effectiveness of using interleukin-12 (IL-12) in combination with intranasally-delivered vaccines to boost immune… Read more . . .
-
According to Meda Pharmaceuticals, a Phase 3 trial has shown that its Dymista nasal spray, a combination formulation of azelastine hydrochloride and fluticasone propionate, produced a 40% greater improvement in nasal symptoms than fluticasone alone.… Read more . . .
-
Vectura’s VR496, an inhaled dry powder formulation of heparin sodium, has produced positive results in a Phase 2 study in cystic fibrosis patients, says the company. The product has received orphan drug status from both… Read more . . .
-
Results from the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) study published in the New England Journal of Medicine show a significant reduction in exacerbations for COPD patients treated with tiotropium compared to those… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.